Capricor Therapeutics, Capricor Therapeutics, Inc. (NASDAQ:CAPR) was founded in 2005 and is headquartered in Beverly Hills, California, USA. It has 38 full-time employees. It is a biotechnology company focusing on the discovery of new therapeutic drugs for the treatment of cardiovascular diseases , Development and commercialization.
Capricor Therapeutics (CAPR):
Capricor Therapeutics’ development stage cardiovascular disease drug candidates include CAP-1002, which is currently in phase II clinical trials; and CAP-2003, which is in the preclinical development stage for the treatment of certain cardiac and inflammatory conditions.
On July 17, 2017, Capricor Therapeutics, Inc.’s experimental drug for the treatment of Duchenne muscular dystrophy obtained the FDA’s rare disease treatment drug designation (orphan drug), and its stock price rose by up to 130%.